Learn more with the 2024 Axol Directory – available for download
iPSCs? What can we do to help?
Supporting drug discovery programs that look to utilize iPSC technology
At Axol, we’re here to support drug discovery researchers who want to harness the power of iPSC-derived models. Like you, we believe that these more human-relevant advanced in vitro models have the potential to unlock better, safer therapies for neurodegenerative and cardiovascular diseases.
We’ve been working with iPSCs in a quality-focused environment for over a decade and have developed a deep understanding of the challenges of this space. Whether it’s compound screening on physiologically useful models, iPSC creation, QC and banking, or the large-scale supply of functionally-relevant cells, we can help you.
Our capabilities include:
High-quality, functionally consistent axoCellsTM, a bank of over 70 fully characterized and licensed axoLinesTM, our QC-rich axoServicesTM, and the ability to work with you to build, validate and use iPSC-based axoModelsTM.
Collaboration is one of our six core company values; we’re here to help you by doing the heavy lifting, so you can focus on the science with reduced risk, shortened project timelines and improved outcomes.
So get in touch below.
Latest News
Explore our current missions:
axoServices™ — custom laboratory services
Outsource your iPSC project to the experts
With over a decade of iPSC expertise, you can rely on us as your first choice for a professional, QC-rich service delivery and an ongoing collaborative relationship. Take a look at how we can do the technical heavy lifting with our full suite of custom lab service projects comprising Reprogramming, Differentiation, Gene Editing, Compound Screening, Multi-Electrode Array and Cell Assays.
Find us on Scientist.com, the world’s leading platform for CROs.
axoLines™ – human-derived cell lines
Fuel your research with iPSC lines from patient and healthy control donors
We’ve developed a diverse library of over 70 iPSC lines derived from a range of fully-consented patient and healthy donors. With full licenses and a 50:50 split of male:female donors, you can use our axoLines iPSCs for axoServices custom lab services, made-to-order axoCells projects and specific licensing arrangements. Key therapy areas include Alzheimer’s Disease, Parkinson’s Disease, ALS, Huntington’s Disease, Friedreich’s Ataxia and Frontotemporal Dementia.
axoCells™ — cells, media and reagents
The first choice for high-quality, functionally relevant iPSC-derived cells
With over a decade of experience, we’ve developed the manufacturing capabilities to produce high-quality, functional iPSC-derived cells with excellent consistency. Your research can benefit from our quality-focused approach, with our catalog of robust, highly relevant iPSC-derived neurons and cardiomyocytes developed at our ISO 9001:2015-accredited production facility. Our leading neuronal cell types include: cortical excitatory neurons, striatal neurons, cortical inhibitory interneurons, microglia, astrocytes, sensory neurons and motor neurons. We also provide high-quality atrial cardiomyocytes and ventricular cardiomyocytes, as well as made-to-order myotubes.
Get in touch to see why we’re the first choice for high-quality, consistent.
Our pledge to the iPSC market
As a company, we have pledged to support the growth of the market by making it simpler and cheaper for groups who want to access iPSC technology, so we’ve developed programs across the spectrum of iPSC users; from first-timers, to those with existing projects, to those who wish to build large systems and scale up. Get in touch with us to see how we can become your first choice in iPSC technology.
Read more about our pledge here.
axoModels™ — robust models, powered by iPSCs
Work with us to build advanced iPSC-based test systems
We’re offering our world-leading iPSC expertise to researchers who want to build better human disease models with exciting translational potential. We work collaboratively to build, assess, and execute projects using functional cells derived from patient and healthy control-derived iPSCs, offering a more useful human-relevant test system for research and compound screening. If you’d like to discuss building a robust model for neurodegenerative drug discovery and cardiotoxicity, get in touch to discuss working with us on an axoModels project.